A detailed history of Meeder Asset Management Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Meeder Asset Management Inc holds 591 shares of VRTX stock, worth $277,013. This represents 0.02% of its overall portfolio holdings.

Number of Shares
591
Previous 521 13.44%
Holding current value
$277,013
Previous $211,000 17.06%
% of portfolio
0.02%
Previous 0.02%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$407.69 - $446.08 $28,538 - $31,225
70 Added 13.44%
591 $247,000
Q4 2023

Jan 25, 2024

BUY
$343.0 - $410.68 $178,703 - $213,964
521 New
521 $211,000
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $219,779 - $245,985
699 Added 6.93%
10,792 $3.8 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $207,607 - $236,832
733 Added 7.83%
10,093 $3.18 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $1.61 Million - $1.81 Million
-5,624 Reduced 37.53%
9,360 $2.7 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $1.49 Million - $1.66 Million
5,425 Added 56.75%
14,984 $4.34 Million
Q2 2022

Aug 08, 2022

BUY
$234.96 - $292.55 $1.3 Million - $1.62 Million
5,536 Added 137.61%
9,559 $2.69 Million
Q1 2022

May 10, 2022

BUY
$221.42 - $260.97 $890,772 - $1.05 Million
4,023 New
4,023 $1.05 Million
Q4 2021

Feb 11, 2022

SELL
$177.01 - $223.45 $2.02 Million - $2.55 Million
-11,404 Closed
0 $0
Q3 2021

Nov 08, 2021

BUY
$181.39 - $202.99 $1.74 Million - $1.94 Million
9,581 Added 525.56%
11,404 $2.07 Million
Q2 2021

Aug 09, 2021

SELL
$187.49 - $221.1 $2.62 Million - $3.08 Million
-13,949 Reduced 88.44%
1,823 $368,000
Q1 2021

Apr 28, 2021

BUY
$207.02 - $241.31 $2.94 Million - $3.43 Million
14,221 Added 916.89%
15,772 $3.39 Million
Q4 2020

Feb 09, 2021

SELL
$207.01 - $276.09 $3.33 Million - $4.45 Million
-16,101 Reduced 91.21%
1,551 $367,000
Q3 2020

Nov 02, 2020

BUY
$255.65 - $303.1 $73,115 - $86,686
286 Added 1.65%
17,652 $4.8 Million
Q2 2020

Aug 11, 2020

BUY
$225.48 - $295.8 $209,470 - $274,798
929 Added 5.65%
17,366 $5.04 Million
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $5.71 Million - $7.09 Million
-28,596 Reduced 63.5%
16,437 $3.91 Million
Q4 2019

Feb 13, 2020

SELL
$166.71 - $223.91 $162,208 - $217,864
-973 Reduced 2.11%
45,033 $9.86 Million
Q3 2019

Oct 17, 2019

BUY
$166.23 - $187.09 $163,237 - $183,722
982 Added 2.18%
46,006 $7.79 Million
Q2 2019

Aug 05, 2019

BUY
$164.61 - $190.37 $742,884 - $859,139
4,513 Added 11.14%
45,024 $8.26 Million
Q1 2019

Apr 16, 2019

BUY
$163.73 - $194.7 $832,567 - $990,049
5,085 Added 14.35%
40,511 $7.45 Million
Q4 2018

Jan 17, 2019

BUY
$151.91 - $192.21 $935,613 - $1.18 Million
6,159 Added 21.04%
35,426 $5.87 Million
Q3 2018

Nov 02, 2018

SELL
$167.73 - $192.74 $32,539 - $37,391
-194 Reduced 0.66%
29,267 $0
Q2 2018

Jul 24, 2018

BUY
$145.72 - $169.96 $1.34 Million - $1.56 Million
9,187 Added 45.31%
29,461 $0
Q1 2018

May 03, 2018

BUY
$151.6 - $177.13 $1.38 Million - $1.61 Million
9,079 Added 81.1%
20,274 $3.31 Million
Q4 2017

Feb 02, 2018

SELL
$137.28 - $155.55 $180,248 - $204,237
-1,313 Reduced 10.5%
11,195 $1.68 Million
Q3 2017

Oct 20, 2017

BUY
$148.13 - $162.24 $1.85 Million - $2.03 Million
12,508
12,508 $1.9 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.